Niranjan Sardesai, PhD

Dr. Niranjan Sardesai is the co-founder of Geneos Therapeutics, a stand-alone venture backed biotherapeutics startup developing exquisitely personalized immunotherapies for cancer based on its proprietary GT-EPIC™ platform. Geneos’ approach treats solid tumors by targeting patients’ tumor specific neoantigens. Niranjan initially launched Geneos through Inovio Pharmaceuticals after building Inovio into a Phase III cancer and infectious disease immunotherapy company serving as its COO. Niranjan has over 25 years in biotech and is passionate about developing novel diagnostics and therapeutics for the treatment of cancer. He is driven in his pursuit to make cancer treatments more efficacious, cost effective, and time efficient after seeing many close family members and colleagues succumb early to cancer. Prior to Inovio, Niranjan founded a consulting firm to provide strategic counsel to entrepreneurial life science companies and served as Director of Research and Development at Fujirebio Diagnostics. Niranjan received his PhD in Chemistry from the California Institute of Technology and MBA from Wharton. He was awarded the Shils-Zeidman Award in Entrepreneurship, fellowships at both the Scripps Research Institute and MIT, has published over 120 peer-reviewed manuscripts, and holds multiple patents. He was recognized by PharmaVoice magazine as one of the top 100 most influential and inspirational leaders across the life sciences industry (2015). Niranjan lives in Blue Bell, PA, USA with his wife and their two sons they are raising to be responsible global citizens.